ResearcherAC Camargo HospitalActive in the last 2 years
Rachel P. Riechelmann
Matched on ORCID iD 0000-0002-0107-9617; OpenAlex author ID A5061506752, A5126471378. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 3, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 7
- Neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherapy in resectable or borderline resectable PDAC: a systematic review and meta-analysis… Last author DOI 10.1177/17588359261449077↗
- Current clinical practice in the management of Brazilian patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1002/jso.27453↗
- Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment… First author DOI 10.1177/10732748221149543↗
- Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective. First author DOI 10.1177/10732748231173212↗
- Disparities in access to health care system as determinant of survival for patients with pancreatic cancer in the State of São Paulo, Brazil. Co-author DOI 10.1038/s41598-021-85759-5↗
- Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic ca… First author DOI 10.3332/ecancer.2021.1276↗
- Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Last author DOI 10.1177/1758835920905408↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Victor Hugo Fonseca de Jesus · 7 shared papers, 2020–2026 · strength 1.92
- Paper Neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherapy in resectable or borderline resectable PDA… DOI 10.1177/17588359261449077↗
- Paper Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective. DOI 10.1177/10732748231173212↗
- Paper Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocar… DOI 10.1177/10732748221149543↗
- Angelo Borsarelli Carvalho Brito · 1 shared paper, 2023 · strength 0.31
- Renata D’Alpino Peixoto · 1 shared paper, 2024 · strength 0.20
- Aldo Lourenço Abbade Dettino · 1 shared paper, 2021 · strength 0.15
- Felipe José Fernández Coimbra · 1 shared paper, 2021 · strength 0.15
- María Paula Curado · 1 shared paper, 2021 · strength 0.15
- Wilson Luiz da Costa · 1 shared paper, 2021 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.